S&P 500   4,581.61 (+0.66%)
DOW   35,664.58 (+0.49%)
QQQ   381.76 (+0.46%)
AAPL   152.03 (+2.14%)
MSFT   322.16 (-0.31%)
FB   309.07 (-1.01%)
GOOGL   2,918.66 (-0.19%)
TSLA   1,060.32 (+2.16%)
AMZN   3,396.24 (+0.11%)
NVDA   246.15 (+0.67%)
BABA   168.70 (-0.31%)
NIO   39.30 (-0.03%)
CGC   12.85 (+0.55%)
GE   104.18 (+0.32%)
AMD   121.53 (-0.61%)
MU   70.32 (+3.05%)
T   25.50 (+1.76%)
F   17.39 (+12.12%)
ACB   6.93 (+1.32%)
DIS   169.25 (-0.18%)
PFE   43.41 (+1.02%)
BA   206.99 (+0.18%)
AMC   35.60 (+2.42%)
S&P 500   4,581.61 (+0.66%)
DOW   35,664.58 (+0.49%)
QQQ   381.76 (+0.46%)
AAPL   152.03 (+2.14%)
MSFT   322.16 (-0.31%)
FB   309.07 (-1.01%)
GOOGL   2,918.66 (-0.19%)
TSLA   1,060.32 (+2.16%)
AMZN   3,396.24 (+0.11%)
NVDA   246.15 (+0.67%)
BABA   168.70 (-0.31%)
NIO   39.30 (-0.03%)
CGC   12.85 (+0.55%)
GE   104.18 (+0.32%)
AMD   121.53 (-0.61%)
MU   70.32 (+3.05%)
T   25.50 (+1.76%)
F   17.39 (+12.12%)
ACB   6.93 (+1.32%)
DIS   169.25 (-0.18%)
PFE   43.41 (+1.02%)
BA   206.99 (+0.18%)
AMC   35.60 (+2.42%)
S&P 500   4,581.61 (+0.66%)
DOW   35,664.58 (+0.49%)
QQQ   381.76 (+0.46%)
AAPL   152.03 (+2.14%)
MSFT   322.16 (-0.31%)
FB   309.07 (-1.01%)
GOOGL   2,918.66 (-0.19%)
TSLA   1,060.32 (+2.16%)
AMZN   3,396.24 (+0.11%)
NVDA   246.15 (+0.67%)
BABA   168.70 (-0.31%)
NIO   39.30 (-0.03%)
CGC   12.85 (+0.55%)
GE   104.18 (+0.32%)
AMD   121.53 (-0.61%)
MU   70.32 (+3.05%)
T   25.50 (+1.76%)
F   17.39 (+12.12%)
ACB   6.93 (+1.32%)
DIS   169.25 (-0.18%)
PFE   43.41 (+1.02%)
BA   206.99 (+0.18%)
AMC   35.60 (+2.42%)
S&P 500   4,581.61 (+0.66%)
DOW   35,664.58 (+0.49%)
QQQ   381.76 (+0.46%)
AAPL   152.03 (+2.14%)
MSFT   322.16 (-0.31%)
FB   309.07 (-1.01%)
GOOGL   2,918.66 (-0.19%)
TSLA   1,060.32 (+2.16%)
AMZN   3,396.24 (+0.11%)
NVDA   246.15 (+0.67%)
BABA   168.70 (-0.31%)
NIO   39.30 (-0.03%)
CGC   12.85 (+0.55%)
GE   104.18 (+0.32%)
AMD   121.53 (-0.61%)
MU   70.32 (+3.05%)
T   25.50 (+1.76%)
F   17.39 (+12.12%)
ACB   6.93 (+1.32%)
DIS   169.25 (-0.18%)
PFE   43.41 (+1.02%)
BA   206.99 (+0.18%)
AMC   35.60 (+2.42%)
NASDAQ:DNAY

Codex DNA Stock Forecast, Price & News

$9.47
-0.13 (-1.35 %)
(As of 10/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.36
$9.59
50-Day Range
$10.15
$14.55
52-Week Range
$9.05
$25.70
Volume
41,230 shs
Average Volume
121,921 shs
Market Capitalization
$277.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive DNAY News and Ratings via Email

Sign-up to receive the latest news and ratings for Codex DNA and its competitors with MarketBeat's FREE daily newsletter.


About Codex DNA

Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries. The company also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DNAY
Employees
101
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$277.40 million
Next Earnings Date
11/9/2021 (Estimated)
Fiscal Year End
December 31
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.63 out of 5 stars

Medical Sector

961st out of 1,372 stocks

Analytical Instruments Industry

23rd out of 30 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Codex DNA (NASDAQ:DNAY) Frequently Asked Questions

Is Codex DNA a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codex DNA in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Codex DNA stock.
View analyst ratings for Codex DNA
or view top-rated stocks.

What stocks does MarketBeat like better than Codex DNA?

Wall Street analysts have given Codex DNA a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Codex DNA wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Codex DNA?

Codex DNA saw a increase in short interest in September. As of September 30th, there was short interest totaling 488,600 shares, an increase of 37.1% from the September 15th total of 356,400 shares. Based on an average daily trading volume, of 123,400 shares, the short-interest ratio is currently 4.0 days. Approximately 5.6% of the company's stock are short sold.
View Codex DNA's Short Interest
.

When is Codex DNA's next earnings date?

Codex DNA is scheduled to release its next quarterly earnings announcement on Tuesday, November 9th 2021.
View our earnings forecast for Codex DNA
.

How were Codex DNA's earnings last quarter?

Codex DNA, Inc. (NASDAQ:DNAY) released its quarterly earnings results on Monday, August, 9th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.36) by $0.70. The company had revenue of $2.85 million for the quarter, compared to the consensus estimate of $2.55 million.
View Codex DNA's earnings history
.

What price target have analysts set for DNAY?

3 equities research analysts have issued 12 month price targets for Codex DNA's shares. Their forecasts range from $16.57 to $30.00. On average, they anticipate Codex DNA's share price to reach $23.19 in the next twelve months. This suggests a possible upside of 144.9% from the stock's current price.
View analysts' price targets for Codex DNA
or view top-rated stocks among Wall Street analysts.

Who are Codex DNA's key executives?

Codex DNA's management team includes the following people:
  • Dr. Todd R. Nelson, Pres, CEO & Director (Age 54, Pay $735.78k)
  • Mr. Daniel G. Gibson, Chief Technology Officer (Age 44, Pay $365.65k)
  • Mr. Timothy E. Cloutier Ph.D., Sr. VP of Commercial Operations (Age 47, Pay $239.11k)
  • Ms. Jennifer Isacoff McNealey M.H.A., Chief Financial Officer (Age 48)
  • Mr. Thomas H. Braden, VP of Global Operations (Age 64)
  • Dr. Madoo Varma Ph.D., VP of Corp. Bus. Devel. (Age 63)
  • Mr. Decky Goodrich M.B.A., VP of Global Sales
  • Ms. Laura B. Puga M.B.A., VP of People & Culture (Age 41)
  • Mr. Dimas Jimenez M.B.A., VP & Corp. Controller (Age 51)
  • Mr. Brent M. Hunter, Sr. Director & Corp. Controller

When did Codex DNA IPO?

(DNAY) raised $100 million in an initial public offering on Friday, June 18th 2021. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen and KeyBanc Capital Markets acted as the underwriters for the IPO.

What is Codex DNA's stock symbol?

Codex DNA trades on the NASDAQ under the ticker symbol "DNAY."

When does Codex DNA's lock-up period expire?

Codex DNA's lock-up period expires on Wednesday, December 15th. Codex DNA had issued 6,666,665 shares in its initial public offering on June 18th. The total size of the offering was $106,666,640 based on an initial share price of $16.00. After the end of Codex DNA's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

How do I buy shares of Codex DNA?

Shares of DNAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Codex DNA's stock price today?

One share of DNAY stock can currently be purchased for approximately $9.47.

How much money does Codex DNA make?

Codex DNA has a market capitalization of $277.40 million.

How many employees does Codex DNA have?

Codex DNA employs 101 workers across the globe.

What is Codex DNA's official website?

The official website for Codex DNA is codexdna.com.

How can I contact Codex DNA?

The company can be reached via phone at 858-228-4115 or via email at [email protected].


This page was last updated on 10/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.